Document is current

Article History

Received: 9 May 2024

Accepted: 28 October 2024

First Online: 20 November 2024

Declarations

:

: The CHESS I and CHESS II studies were approved by the Research Ethics Sub Committee of the Faculty of Health and Social care within the University of Chester and conducted in correspondence with regional and relevant guidelines. Patient consent for use of clinical data was not required (as per European Pharmaceutical Market Research Association [EPhMRA] guidelines). Patient consent was obtained via tick box selection for the patient-reported element of the studies.

: Not applicable.

: This study was sponsored by Pfizer Ltd. TB and EFG are employees of HCD Economics Ltd., which was a paid consultant to Pfizer Ltd. in connection with the development of this manuscript and for study design, data analysis and interpretation. EFG: Speakers’ bureau: Sobi, Roche, Novo Nordisk, BioMarin, CSL Behring; Advisory boards: Sobi, Roche, BioMarin, Pfizer. IW and LR are employees of Pfizer Ltd., the study sponsor. JOH was an employee of HCD Economics Ltd. during the conduct of the study. IW, AC, JB and LR were employees of Pfizer Ltd. during the conduct of this study. JB is currently employed by BioMarin Pharmaceutical Inc. ML was a paid consultant to Pfizer Ltd. in relation to study design and data interpretation for this study and also declares the following: Consultant to AstraZeneca, Silence, Hemab; Research grant support from BioMarin; Speaker fees from Pfizer, Bayer, Takeda, Leo Pharma, Sobi, AstraZeneca, Chugai/Roche; Advisory boards: Takeda, LFB, Roche/Chugai, Sobi, Bayer, Pfizer, CSL Behring, BioMarin. JG was a paid consultant to Pfizer Ltd. in relation to study design and data interpretation for this study and has been a paid consultant to HCD Economics Ltd. in relation to a separate haemophilia study.